Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2006-07-27
2011-10-04
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Reexamination Certificate
active
08030443
ABSTRACT:
Provided is a squamous cell carcinoma antigen derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of squamous cell carcinoma.
REFERENCES:
patent: 6555652 (2003-04-01), Itoh et al.
patent: 1 640 018 (2006-03-01), None
patent: 00/09075 (2000-02-01), None
patent: WO0142277 (2001-06-01), None
Harig et al , Blood, vol. 98, p. 2999-3005, 2001.
Mine et al, Cancer Sci, 94:548-556, 2003.
Schineider et al , PNAS, vol. 92, p. 3147-51, 1995.
Sequence search result (U19556), 2010.
International Search Report issued Oct. 10, 2006 in corresponding International (PCT) Application No. PCT/JP2006/314896.
Supplemental European Search Report issued Sep. 25, 2009 in corresponding European Application No. PCT/JP2006/314896.
Kato et al; “Radioimmunoassay for Tumor Antigen of Human Cervical Squamous Cell Carcinoma”; Cancer, American Cancer Society; Philadelphia, PA, US; vol. 40, No. 4; c. Jan. 1977; p. 1621-1628.
Masahide et al; “Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens”; Anticancer Research, International Institute of Anticancer Research, GR; vol. 23, No. 6a, c. Nov. 2003; p. 4377-4381.
Kuroki et al.; “Significance of tumor-associated antigens in the diagnosis and therapy of cancer: An overview” Anticancer Research, International Institute of Anticancer Research, GR, vol. 22, No. 6C, Jan. 2002; p. 4255-4264.
Ito et al.; “7-: Gan KogenPeptide Vaccine Idenshi Dotei kara Rinsho Kenkyu e”; Nichigai Kaishi, c. Jan. 2000; vol. 101, No. 9; p. 612-617.
Tahara et al.; “Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes”; Clinical Cancer Research; c. 1999; vol. 5, No. 8; p. 2236-2241.
Toyoshima et al.; “Koku Henpei Johi Gan Kanja ni Okeru Shuyo Shui no Lymphocyte Shinjun to Koshuyo Saibo Shogaisei T Saibo no in vitro Yudo tono Kanren”; 63rd Annual Meeting of the Japan Cancer Association Kiji; c. Aug. 2004; p. 301; (lecture No. P-0763).
Kamura, “Fujinka Gan Peptide Vaccine no Rinsho Kenkyu ni Kansuru Kenkyu”; Kosei Rodo Kagaku Kenkyu Kenkyuhi Hojokin Kiso Kenkyu Seika no Rinsho Oyo Suishin Kenkyu Jigyo Gan Chiryo Peptide Vaccine Dyobi Peptide Kotai Kaihatsu: Idenshi Dotei kara Rinsho Shiken Madeni Kansuru Kenkyu; c. May 2005; Heisei 16 Nendo Sokatsu Kenkyu Hokokusho; p. 23-25.
Fumiaki Tanaka et al., “Jujo Saibo o Mochiita Gan Tokui Men'eki Chiryo”; Gendai Iryo; c. Jul. 2004; vol. 36, No. 7; p. 191-195.
Schneider et al.; “Human squamous cell carcinoma antigen 1 (8CCA1) mRNA”; c. Nov. 1995; NCBI Entrez Nucleotide, Accession U19556; Retrieved from the internet:<URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?1052868: OLDID:1802152.
Yamanaka; “Akusei Shinkei Koshu ni Taisuru Peptide Vaccine no Rinsho Kenkyu ni Kansuru Kenkyu”, Kosei Rodo Kagaku Kenkyu Kenkyuhi Hojokin Kiso Kenkyu Seika no Rinsho Oyo Suishin Kenkyu Jigyo Gan Chiryo Peptide Vaccine Oyobi Peptide Kotai Kaihatsu: Idenshi Dotei kara Rinsho 8hiken Madeni Kansuru Kenkyu; c. May 2005; Heisei 16 Nendo Sokatsu Kenkyu Hokokusho; p. 45-48.
M1MURA et al.; “HLA-A24 Kosokusei HER2 Epitope Dotei to Gan Vaccine Ryoho”; Japanese Journal of Cancer and Chemotherapy, Oct. 2003; vol. 30, No. 11, p. 1802-1804.
Hagihara et al.; “The in vitro generation of Ph1+ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr-abl peptide”; Leukemia Research; c. 2003, vol. 27, No. 3, p. 253-257.
Nishiyama et al.; “Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigenA24-specific MAGE-3 peptide”; Clinical Cancer Research; c. 2001; vol. 7, No. 1; p. 23-31.
Parker et al.; “Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains”; The Journal of Immunology; c. 1994; vol. 152, No. 1, p. 163-175.
Homma et al.; “Identification of Squamous Cell Carcinoma Antigen-Derived Peptides Having the Capacity of Inducing Cancer-Reactive CTLs in HLA-A24+ Cancer Patients”; International Journal of Oncology; c. 2006; vol. 29, No. 3; p. 577-587.
Kato et al; “Radioimmunoassay for Tumor Antigen of Human Cervical Squamous Cell Carcinoma”; Cellular & Molecular Biology; c. 1979; No. 25; p. 51-56.
Takeshima et al.; “Origin of CA125 and SCC Antigen in Human Amniotic Fluid”; Asia-Oceania Journal of Obstetrics/Gynecology; c. 1993; vol. 19, No. 2; p. 199-204.
Kato et al; “Tumor Antigen of Human Cervical Squamous Cell Carcinoma”; Cancer, American Cancer Society; Philadelphia, PA, US; vol. 43; c. 1979; p. 585-590.
Lara et al.; “The Role of Squamous Cell Carcinoma Antigen in the Management of Laryngeal and Hypopharyngeal Cancer”; Cancer; c. Sep. 1995; vol. 76, No. 5; p. 758-764.
Snyderman et al.; “A Reappraisal of the Squamos Cell Carcinoma Antigen as Tumor Marker in Head and Neck Cancer”; Arch Otolaryngol Head Neck Surgery; c. Nov. 1995; vol. 121; p. 1294-1297.
Hefler et al; “Serum Concentrations of Squamous Cell Carcinoma Antigen in Patients with Vulvar Intraepithelial Neoplasia and Vulvar Cancer”; Int. Journal of Cancer (Fred. Oncol.); Wiley-Liss, Inc.; c. 1999; vol. 84; p. 299-303.
Senekjian et al.; “An Evaluation of Squamous Cell Carcinoma Antigen in Patients with Cervical Squamous Cell Carcinoma”; American Journal for Obstetrics and Gynecology; c. 1987; vol. 157; p. 433-439.
Duk et al.; “Cancer of the Uterine Cervix: Sensitivity and Specificity of Serum Squamous Cell Carcinoma Antigen Determinations”; Gynecological Oncology; c. 1990; vol. 39; p. 186-194.
Bolli et al.; “Squamous Cell Carcinoma Antigen: Clinical Utility in Squamous Cell Carcinoma of the Uterine Cervix”; Gynecological Oncology; c. 1994; vol. 55; p. 169-173.
Daver et al.; “Intérêt diagnostique du dosage du SCC-TA4 dans quatre localisations de cancers épidermoïdes. Expérience di sous-groupe de radio-analyse de la FNCLCC”; Bull Cancer; Elsevier, Paris; c. 1990; vol. 77; p. 781-792.
Bolger et al.; “Prognostic Value of Preoperative Squamous Cell Carcinoma Antigen Level in Patients Surgically Treated for Cervical Carcinoma”; Gynecological Oncology; Academic Press; c. 1997; vol. 65; Article No. G0974619; p. 309-313.
Ito et al.; “Molecular Basis of T Cell-mediated Recognition of Pancreatic Cancer Cells”; Cancer Research; c. Mar. 2001; vol. 61; p. 2038-2046.
Shichijo et al.; “A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes”; The Journal of Experimental Medicine; The Rockefeller University Press; c. 1998; vol. 187, No. 3; p. 277-288.
Yang et al.; “Identification of a Gene Coding for a Protein Possessing Shared Tumor Epitopes Capable of Inducing HLA-A24-restricted Cytotoxic T Lymphocytes in Cancer Patients”; Cancer Research; c. Aug. 1999; vol. 59; p. 4056-4063.
Noguchi et al.; “Induction of Cellular and Humoral Immune Responses to Tumor Cells and Peptides in HLA-A24 Positive Hormone-Refractory Prostate Cancer Patients by Peptide Vaccination”; Prostate; Wiley-Liss, Inc.; c. 2003; vol. 57; pp. 80-92.
Sato et al.; “Immunological Evaluation of Peptide Vaccination for Patients with Gastric Cancer Based on Pre-Existing Cellular Response to Peptide”; Cancer; c. Sep. 2003; vol. 94, No. 9; p. 802-808.
Mine et al.; “Immunological Evaluation of CTL Precursor-Oriented Vaccines for Advanced Lung Cancer Patients”; Cancer Science; c. Jun. 2003; vol. 94, No. 6; p. 548-556.
Tsuda et al.; “Vaccination with Predesignated or Evidence-Based Peptides for Patients with Recurrent Gynecologic Cancer
Harada Mamoru
Itoh Kyogo
Kurume University
Wenderoth , Lind & Ponack, L.L.P.
Yao Lei Yaolei
Yu Misook
LandOfFree
Squamous cell carcinoma antigen-derived peptide binding to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Squamous cell carcinoma antigen-derived peptide binding to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Squamous cell carcinoma antigen-derived peptide binding to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4291849